TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00852306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte freezing
Description: retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
Study: NCT00714129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (calorie restricted diet)
Description: Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (calorie restricted diet)
Description: Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
Study: NCT00605735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-582949
Description: Tablets, Oral, 300 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, placebo, once daily, 12 weeks
Study: NCT02273791

Intervention type: DRUG
Intervention: Estradiol valerate
Description: Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.

Intervention type: DRUG
Intervention: Sequential Clomiphene citrate and Gonadotropin
Description: Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
Study: NCT04666415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
Study: NCT04407494

Intervention type: BIOLOGICAL
Intervention: Reporting of anosmia, ageusia and other clinical symptoms
Description: Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
Study: NCT03738020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF (YVOIRE classic)
Description: Treatment with HA IDF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Treatment with Restylane
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 2x5 mg/kg BW, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14g/m² BS, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² BS, 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² BS, 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: iV, dosage according therapeutic drug monitoring, 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: iV, dosage according therapeutic drug monitoring, 4 days
Study: NCT03371342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin (Botulinum toxin type A)
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Thymoglobulin
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Thymoglobulin
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG Thymoglobulin
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Study: NCT03371342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox(Botulinum toxin type A)
Study: NCT01654523

Intervention type: DEVICE
Group type: OTHER
Intervention: Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
Description: Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
Study: NCT03094832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Study: NCT03094832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grafalon
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Study: NCT02381964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® (1RDA+CoQ10)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® (3RDA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01514721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Timolol Maleate BAK-Free Fixed Combination
Description: Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
Study: NCT00920478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musculoskeletal Ultrasound
Description: Gray scale and power doppler - to identify the presence of synovitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 28 Joint Disease Activity Score
Description: Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
Study: NCT03693118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reh1,Reh2
Description: The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reh1,Reh2
Description: The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
Study: NCT01663844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia w. extra support
Description: (Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
Study: NCT01288157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Single dose of 100 mg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Single dose of 50 mg subcutaneously
Study: NCT02691026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT01663844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist guided Internet-CBT for insomnia
Description: (Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia and depression
Description: (Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Guided Internet-CBT for depression plus insomnia placebo
Description: (Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
Study: NCT01882244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural Pathfinder Training
Description: Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
Study: NCT00335998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study: NCT04618588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Window Sinus Lift technique
Description: Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement
Study: NCT00335998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo intracavitary or interstitial brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01796288

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: simultaneous radiotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT02193997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02405988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Description: Administer 2,5 mL, dose intravenous naloxone 1,0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
Study: NCT02765048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAIN Program
Description: Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
Study: NCT01474304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
Study: NCT02189798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode
Description: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS sound processor
Description: Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS sound processor
Description: Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS sound processor
Description: Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
Study: NCT02593058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotions Program for Schizophrenia
Description: Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
Study: NCT00587769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR & Varenicline
Description: Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
Study: NCT01728142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANA Brief
Description: The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DANA Brief
Description: The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANAM
Description: The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANAM
Description: The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
Study: NCT02874443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation of labor management guidelines
Study: NCT02102243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY® infusion
Description: The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
Study: NCT03334474

Intervention type: OTHER
Description: no intervention
Study: NCT02102243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
Study: NCT02055950

Intervention type: PROCEDURE
Intervention: Storage of kidney in refrigerated solution

Intervention type: PROCEDURE
Intervention: Kidney perfused by pulsatile machine
Study: NCT01626573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Study: NCT01626573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo
Study: NCT02025998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
Study: NCT01754207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with CAP Array
Description: 755nm Alexandrite Laser with CAP Array